A multidisciplinary approach to the control of the calcium x phosphate product in dialysis patients

被引:0
|
作者
Hoar, S [1 ]
Morton, AR
Meers, C
Mulkerns, S
Lawlor, M
Toffelmire, EB
机构
[1] Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada
[2] Queens Univ, Dept Pharmacol & Toxicol, Kingston, ON K7L 3N6, Canada
[3] Kingston Gen Hosp, Dept Nutr Serv, Kingston, ON K7L 2V7, Canada
[4] Kingston Gen Hosp, Dept Nursing, Kingston, ON K7L 2V7, Canada
关键词
D O I
暂无
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Hyperphosphatemia is common in dialysis patients. With the use of calcium-based phosphate binders and calcitriol, hypercalcemia is also frequently encountered. This combination leads to elevations of the calcium:phosphate product. A product of >2.5 mmol(2)/L-2 (ionized calcium x phosphate [iCa x P]) may increase the risk of periarticular, conjunctival, vascular, and visceral calcifications. A comprehensive multi-disciplinary program was implemented in an effort to control the iCa x P in our dialysis population. This program consisted of an educational package ("A Taste for Life," Abbott Renal Care) delivered by nursing staff; concentrated reviews and advice by dietitians; and reviews, reinforcement, and medication adjustments by nephrologists. The adequacy of the intervention was assessed by comparing baseline iCa x P with that obtained after 3 and 6 months, and by comparing the percentage of patients with iCa x P >2.5 mmol(2)/L-2 before and after the intervention. The program was administered to 112 dialysis patients (43 PD, 69 HD). Baseline iCa was similar for PD and HD patients, but phosphate was significantly lower in PD vs. HD (1.40 +/- 4 vs. 1.84 +/- 0.48 mmol/L; p = 0.0001). Thus, iCa x P was also lower in the PD group (1.78 +/- 54 vs. 2.3 +/- 6; p = 0.0001). Twenty-eight (25%) of patients had iCa x P >2.5 (5 PD, 23 HD). iCa x P fell to 1.69 +/- 0.67 (PD) and 2.06 +/- 0.5 (HD) at 3 months (n = 112) and was 185 +/- 0.5 (PD) and 2.01 +/- 0.5 (HD) at 6 months (n = 102). Repeated measures of ANOVA showed a significant fall in both phosphate (p = 0.014) and iCa x P (p = 0.012) over 6 months for the whole group. Six months after initiation of the program, 13 (13%) of patients had iCa x P >2.5 (chi(2) = 5.18; p = 0.023 cf baseline). Significant improvements in phosphate control-and, thus, iCa x P-were achieved (most notably in HD patients) by this multidisciplinary approach. iCa x P has been adopted as a quality indicator by our program.
引用
收藏
页码:309 / +
页数:4
相关论文
共 50 条
  • [1] K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them?
    Wei, Mingxin
    Taskapan, Hulya
    Esbaei, Khaled
    Jassal, Sarbjit Vanita
    Bargman, Joanne M.
    Oreopoulos, Dirnitrios G.
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2006, 38 (3-4) : 739 - 743
  • [2] K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them?
    Mingxin Wei
    Hulya Taskapan
    Khaled Esbaei
    Sarbjit Vanita Jassal
    Joanne M. Bargman
    Dimitrios G. Oreopoulos
    International Urology and Nephrology, 2006, 38 : 739 - 743
  • [3] Can Calcium, Phosphate, Calcium Phosphate Product and Intact Parathyroid Hormone Levels Be Appropriately Controlled in Dialysis Patients?
    Deger, S. M.
    Mutluay, R.
    Derici, U.
    Mandiralioglu, F.
    Arinsoy, T.
    Sindel, S.
    MEDICAL PRINCIPLES AND PRACTICE, 2011, 20 (01) : 85 - 89
  • [4] Dietary and Pharmacological Control of Calcium and Phosphate Metabolism in Dialysis Patients
    Bover, J.
    Andres, E.
    Lloret, M. J.
    Aguilar, A.
    Ballarin, J.
    BLOOD PURIFICATION, 2009, 27 (04) : 369 - 386
  • [5] Calcium and Phosphate Control by Dialysis Treatments
    Messa, Piergiorgio
    Cerutti, Roberta
    Brezzi, Brigida
    Alfieri, Carlo
    Cozzolino, Mario
    BLOOD PURIFICATION, 2009, 27 (04) : 360 - 368
  • [6] CALCIUM AND PHOSPHATE BALANCE IN DIALYSIS PATIENTS
    WINCHESTER, JF
    ROTELLAR, C
    GOGGINS, M
    ROBINO, D
    RAKOWSKI, TA
    ARGY, WP
    KIDNEY INTERNATIONAL, 1993, 43 : S174 - S178
  • [7] Achieving calcium and phosphate control in the dialysis unit
    Kirschbaum, B
    DIALYSIS & TRANSPLANTATION, 1996, 25 (04) : 177 - &
  • [8] Multidisciplinary education approach to optimize phosphate control among hemodialysis patients
    Meei Wah Chan
    Huey Miin Cheah
    Madihah Binti Mohd Padzil
    International Journal of Clinical Pharmacy, 2019, 41 : 1282 - 1289
  • [9] Multidisciplinary education approach to optimize phosphate control among hemodialysis patients
    Chan, Meei Wah
    Cheah, Huey Miin
    Padzil, Madihah Binti Mohd
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (05) : 1282 - 1289
  • [10] Calcium phosphate product (CaP), nutritional status and patient outcome in Chinese peritoneal dialysis patients.
    Wang, X
    Dong, J
    Wang, HY
    Wang, T
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 206A - 206A